Epirium Bio is a biopharmaceutical company that has identified and established an IP-protected platform of orally bioavailable small molecules that leverages the potential of PGE-2 signaling to restore tissue homeostasis, resolving aberrant inflammation, stimulating regeneration, and reducing fibrosis. Our oral therapies have the potential to improve function in neuromuscular diseases including sarcopenia, inflammatory and fibrotic diseases.
Our lead small molecule, MF-300 is currently in a Phase 2b study in sarcopenia, and we have generated preclinical efficacy data across a broad scope of indications with significant unmet medical need, including spinal muscular atrophy (SMA), irritable bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).
